In KEYNOTE-522, early-stage TNBC patients on the immunotherapy and chemotherapy combination benefitted regardless of their PD-L1 expression status.
At the NCI's Childhood Cancer Data Initiative Symposium, speakers emphasized measures such as data harmonization and the need for longitudinal data collection.
The grant recipients will receive up to $5 million each and are led by scientists at institutions including Harvard Medical School and the Cleveland Clinic.
The successful development of new targeted tissue-agnostic cancer drugs will be tied to the use of real-world data and new clinical trial formats.
Despite plenty of hype and some growing pains, artificial intelligence is starting to prove its value in academic and community cancer centers.
The TATTON study found a combination therapy could treat some EGFR-positive lung cancer patients who developed MET-based resistance, but the best way to gauge MET status isn't yet clear.
A study presented at the AACR meeting showed that Resolution's ctDx-Lung assay reported more oncogenic fusions than Guardant360 in NSCLC patients.
The researchers believe using cerebral spinal fluid will enable them to identify brain tumors with a higher sensitivity than with blood samples.
The researchers also reported that combining an ER-directed therapy with an irreversible HER2 kinase inhibitor could overcome resistance.
Using a mouse model of immunotherapy resistant disease, the researchers found that this program could be targeted by an inhibitor to improve response.